JW (Cayman) Therapeutics Co Ltd
HKEX:2126
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
|
CN |
|
V
|
Vinci SA
OTC:VCISY
|
FR |
|
Synergy Group Holdings International Ltd
HKEX:1539
|
HK |
|
Gryphon Digital Mining Inc
NASDAQ:ABTC
|
US |
|
M
|
Megaworld Corp
XPHS:MEG
|
PH |
JW (Cayman) Therapeutics Co Ltd
JW (Cayman) Therapeutics Co. Ltd. operates as a clinical stage cell therapy platform company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-11-03. The firm is focuses on developing cell therapies for the China market to transform the treatment of cancer for Chinese patients. Through its subsidiary, it has built an integrated platform focused on developing, manufacturing and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its main product candidate, relmacabtagene autoleucel (relma-cel), is an autologous anti-CD19 CAR-T therapy for relapsed or refractory (r/r) B-cell lymphoma. The firm mainly conducts its businesses in the China market.
JW (Cayman) Therapeutics Co. Ltd. operates as a clinical stage cell therapy platform company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-11-03. The firm is focuses on developing cell therapies for the China market to transform the treatment of cancer for Chinese patients. Through its subsidiary, it has built an integrated platform focused on developing, manufacturing and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its main product candidate, relmacabtagene autoleucel (relma-cel), is an autologous anti-CD19 CAR-T therapy for relapsed or refractory (r/r) B-cell lymphoma. The firm mainly conducts its businesses in the China market.
